Skip to main content

Table 1 Demographic and baseline patient characteristics

From: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

Characteristics No of patients (n = 14) Percent
Gender   
 Male 6 42.9
 Female 8 57.1
Age, median (range)/years 56.5 (14-81)
Performance status (ECOG)  
 0–1 13 92.9
 2 1 7.1
Stage at diagnosis (Masaoka-Koga)   
 IVa 3 21.4
 IVb 8 57.1
 Recurrence 3 21.4
Metastatic sites (overlapped)   
 Lung 6  
 Liver 2  
 Lymph nodes 5  
 Pleura 5  
 Bone 3  
 Brain 1  
Histologic subtype   
 Squamous cell carcinoma 12 85.7
 Lymphoepithelioma-like carcinoma 1 7.1
 Undifferentiated carcinoma 1 7.1
Previous chemotherapy   
 ADOC 3  
 Cisplatin-irinotecan 9  
 Cisplatin-gemcitabine 1  
 Carboplatin-gemcitabine 1  
  1. No number, ADOC cisplatin, adriamycin, vincristine, and cyclophosphamide